Metronomic Chemotherapy in Elderly Non-fit Patients With Aggressive B-Cell Lymphomas
NCT ID: NCT03161054
Last Updated: 2021-12-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
21 participants
INTERVENTIONAL
2017-09-12
2021-06-21
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* DE: Prednisone (Deltacortene) 25 mg /day will be orally administered from day 1 to day 28 only in cycle 1 From cycle 2 to 6 it is reduced to three times a week (after breakfast, MON, WED, FRI)
* V: Vinorelbine 30 mg/day will be orally administered three times a week, 3 week on and 1 week off (after breakfast, MON, WED, FRI).
* E: Etoposide 50 mg/day will be orally administered from day 1 to day 14 (before lunch).
* C: Cyclophosphamide 50 mg/day will be orally administered from day 1 to day 21 (after dinner).
* Rituximab: 375 mg/m2 will be administered by IV infusion up to four infusions on days 8, 15, 22, 29, only in patients suitable for infusion treatment and relapsed after \>6 months from last R-chemotherapy. Refractory patients who had received at least 5 doses of Rituximab will not repeat it during the metronomic therapy.
Super-frail patients will not receive etoposide during cycles 1 and 2; etoposide will be included in the treatment schedule starting from cycle 3 at reduced dose (50 mg/day, from day 1 to day 7) only in patients who in cycles 1 and 2 didn't experience hematological toxicity \>G2 and/or non-hematological toxicity \>G1.
In Unfit and Frail patients with hemoglobin level at study entry \<11 gr/dL, will start etoposide will be orally administered at reduced dose (50 mg/day from day 1 to day 7). If hemoglobin will raise to ≥11 gr/dL, at subsequent induction cycles etoposide will be administered at full dose (50 mg/day, from day 1 to day 14), As a preventive measure, to avoid perforation, patients with gastrointestinal visceral involvement will receive a pre-phase therapy with steroids (prednisolone 40mg/m2
) for 6-7 days before starting protocol treatment. Moreover, in these patients the four Rituximab doses will be administered in cycle 2.
Patients in CR, CRu, PR and SD after 2 cycles will continue with additional 4 courses.
At the end of the induction phase patients in CR, CRu and PR (and also in SD at discretion of local investigator) will continue treatment with maintenance therapy including Vinorelbine, Cyclophosphamide, and Prednisone oral combination to be repeated every 28 days for up to 6 cycles, according to the following schedule:
* Cyclophosphamide 50 mg/day will be orally administered from day 1 to day 14 (after dinner).
* Vinorelbine 30 mg/day will be orally administered three times a week, 3 week on and 1 week off (after breakfast, MON, WED, FRI).
* Prednisone 25 mg/day will be orally administered twice a week (after breakfast, MON, FRI).
Patients in CR/CRu at the EOT can continue with a post-maintenance phase at discretion of the local investigator up to 12 months, progression or inacceptable toxicity, according to following schedule:
* Vinorelbine 30 mg/day will be orally administered three times a week, 3 week on and 1 week off (after breakfast, MON, WED, FRI).
* Prednisone 25 mg/day will be orally administered twice a week (after breakfast, MON, FRI).
Patients with evidence of Progressive Disease (PD) at any point will stop treatment.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
One arm for all patient
Induction phase:
Eligible Pts will receive 6 cycles (every 28 days) of the DEVEC combination: DE: Prednisone, V: Vinorelbine, E: Etoposide, C: Cyclophosphamide and R:Rituximab ; R will be administered only in patients suitable for infusion treatment and relapsed after \>6 months from last R-chemotherapy. Refractory patients who received at least 5 doses of R will not repeat it during the metronomic therapy.
Super-frail patients will not receive etoposide during cycles 1 and 2.
Maintenance Phase:
Pts in CR, CRu and PR at the end of the induction phase, will continue treatment with maintenance therapy including Vinorelbine, Cyclophosphamide, and Prednisone oral combination to be repeated every 28 days for up to 6 cycles.
Post Maintenance Phase:
Pts in CR/CRu at the EOT may, at discretion of the local investigator, continue maintenance with only Vinorelbine and Prednisone for up to further 12 months, progression or inacceptable toxicity at the same doses of maintenance
Prednisone
Induction Phase: Prednisone (Deltacortene) 25 mg /day will be orally administered from day 1 to day 28 only in cycle 1 From cycle 2 to 6 reduce to three times a week (after breakfast).
Maintenance Phase: Prednisone 25 mg/day will be orally administered twice a week continuously (after breakfast).
Post Maintenance Phase: Prednisone 25 mg/day will be orally administered twice a week continuously (after breakfast).
Vinorelbine
Induction Phase: Vinorelbine 30 mg/day will be orally administered three times a week, 3 weeks on and 1 week off (after breakfast).
Maintenance Phase: Vinorelbine 30 mg/day will be orally administered three times a week, 3 weeks on and 1 week off (after breakfast).
Post Maintenance Phase: vinorelbine 30 mg/day will be orally administered three times a week, 3 weeks on and 1 week off (after breakfast).
Etoposide
Induction Phase Etoposide: 50 mg/day will be orally administered from day 1 to day 14 (before lunch); Superfrail patients only from cycle 3, 50 mg/day, from day 1 to day 7
Cyclophosphamide
Induction Phase: Cyclophosphamide 50 mg/day will be orally administered from day 1 to day 21 (after dinner).
Maintenance Phase: 50 mg/day will be orally administered from day 1 to day 14 (after dinner).
Rituximab
Induction Phase: Rituximab: 375 mg/m2 will be administered by IV infusion up to four infusions on days 8, 15, 22, 29, only in patients suitable for infusion treatment and relapsed after \>6 months from last R-chemotherapy. Refractory patients who received at least 5 doses of Rituximab will not repeat it during the metronomic therapy.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Prednisone
Induction Phase: Prednisone (Deltacortene) 25 mg /day will be orally administered from day 1 to day 28 only in cycle 1 From cycle 2 to 6 reduce to three times a week (after breakfast).
Maintenance Phase: Prednisone 25 mg/day will be orally administered twice a week continuously (after breakfast).
Post Maintenance Phase: Prednisone 25 mg/day will be orally administered twice a week continuously (after breakfast).
Vinorelbine
Induction Phase: Vinorelbine 30 mg/day will be orally administered three times a week, 3 weeks on and 1 week off (after breakfast).
Maintenance Phase: Vinorelbine 30 mg/day will be orally administered three times a week, 3 weeks on and 1 week off (after breakfast).
Post Maintenance Phase: vinorelbine 30 mg/day will be orally administered three times a week, 3 weeks on and 1 week off (after breakfast).
Etoposide
Induction Phase Etoposide: 50 mg/day will be orally administered from day 1 to day 14 (before lunch); Superfrail patients only from cycle 3, 50 mg/day, from day 1 to day 7
Cyclophosphamide
Induction Phase: Cyclophosphamide 50 mg/day will be orally administered from day 1 to day 21 (after dinner).
Maintenance Phase: 50 mg/day will be orally administered from day 1 to day 14 (after dinner).
Rituximab
Induction Phase: Rituximab: 375 mg/m2 will be administered by IV infusion up to four infusions on days 8, 15, 22, 29, only in patients suitable for infusion treatment and relapsed after \>6 months from last R-chemotherapy. Refractory patients who received at least 5 doses of Rituximab will not repeat it during the metronomic therapy.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* LBCL1
* DLBCL;
* Grade IIIb follicular lymphoma;
* BL1;
* B-Cell unclassifiable lymphomas with features intermediate between DLBCL and BL or between DLBCL and Hodgkin's lymphoma (HL)35;
* High grade B-cell lymphomas1
* Age \>65 years
* Unfit or frail patients (the latest defined, for the purpose of this study, as those who have a maximum of 1 frail factor) according to the multidimensional geriatric evaluation model of the elderly platform of the FIL, who relapsed/progressed after one or maximum two previous lines of treatment or
* "Super-frail" elderly patients at disease onset: eligible super-frail patients are defined, for the purpose of this study, as those who have a maximum of 2 frail factors, according to the CGA adopted in the elderly platform of the FIL, among those below listed:
* ADL ≤ 4;
* IADL ≤ 5;
* Age ≥ 80 years;
* 1 CIRS grade 3 or \>8 CIRS grade 2.
* Ann Arbor stage I bulky to IV
* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
* Life expectancy \>1-2 months.
* Adequate renal function (creatinine ≤ 2 mg/dl, unless secondary to lymphoma).
* Adequate liver function (bilirubin ≤ 2 mg/dl, unless secondary to lymphoma).
* Absolute neutrophil count (ANC) ≥1500 cells/mmc and platelets ≥ 50,000 cells/mmc, haemoglobin ≥ 9 gr/dl, unless cytopenia is related to bone marrow involvement by lymphoma.
* Availability of adequate care by family members or other caregivers.
* Written informed consent signature.
* Male Subjects must agree to use a latex condom during sexual contact with females of childbearing potential while participating in the study and for at least 3 months following the end or the discontinuation from the study treatment even if he has undergone a successful vasectomy.
Exclusion Criteria
* Relapsed/refractory patients with fit profile.
* Fit, unfit, and frail patients at disease onset.
* Malabsorption syndrome or other diseases that affect the ability to swallow oral therapy.
* Concomitant malignancy requiring treatment (except non-melanoma skin cancers and in situ carcinoma of the uterine cervix).
* Presence of opportunistic infections in place.
* Seropositive for or active viral infection with hepatitis B virus (HBV):
1. HBsAg positive;
2. HBsAg negative, HBcAb positive with detectable viral DNA (Subjects who are HBsAg negative, HBcAb positive, but viral DNA negative are eligible.
* Seropositive and active infection for hepatitis C virus (subjects who are HCV-RNA negative are eligible).
* Known seropositive for or active viral infection with human immunodeficiency virus (HIV).
* Impossibility to give written informed consent.
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fondazione Italiana Linfomi - ETS
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Francesco Merli, MD
Role: PRINCIPAL_INVESTIGATOR
AUSL - IRCCS Arcispedale Santa Maria Nuova viale Risorgimento 80 42123, Reggio Emilia
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
A.O. Spedali Civili di Brescia - Ematologia
Brescia, , Italy
Ospedale di Castelfranco Veneto - Ematologia
Castelfranco Veneto, , Italy
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.) - Ematologia
Meldola, , Italy
Ospedale Guglielmo da Saliceto - U.O.Ematologia
Piacenza, , Italy
Ospedale delle Croci - Ematologia
Ravenna, , Italy
Azienda Ospedaliera Arcispedale Santa Maria Nuova - IRCCS c/o CORE (II piano) - Ematologia
Reggio Emilia, , Italy
AO Sant'Andrea - Ematologia
Roma, , Italy
Nuovo Ospedale Civile di Sassuolo - Day Hospital Oncologico
Sassuolo, , Italy
AOU Senese - U.O.C. Ematologia
Siena, , Italy
A.O.U. Citta della Salute e della Scienza di Torino - Ematologia Universitaria
Torino, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FIL_DEVEC
Identifier Type: -
Identifier Source: org_study_id